SCHEMBL25146397

SCHEMBL25146397

CC(=O)/C=C/C(=O)NCCCCCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.61
PRMT1 Q99873 1/20 0.55
POLB P06746 1/20 0.50
EPHX2 P34913 10/20 0.47
PLA2G2A P14555 1/20 0.47
MAPK1 P28482 1/20 0.46
PLA2G4A P47712 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16579816 1.00 ADRA1A (0.61) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL25146459 0.98 ADRA1A (0.58) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL25146989 0.93 ADRA1A (0.50) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL8779381 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL11133946 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL515857 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL24686717 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL11137045 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL81977 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A
SCHEMBL8779440 0.85 PRMT1 (0.59) ADRA1APRMT1POLBEPHX2PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF PPID, PPIF, PPIL1 ADRA1A 2184/4885PRMT1 4221/4885POLB 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.